Andrew Sandham, executive chairman, Syntaxin
pharmafile | October 20, 2009 | Appointment | Research and Development |Â Â appointment, appointments, research and development, syntaxinÂ
Syntaxin, a biopharmaceutical company developing novel biologic drugs that control cell secretion, has appointed Andrew Sandham executive chairman.
This follows the resignation of chief exeuctive, Patrick Doyle, for personal reasons. Mr Sandham has worked closely with Syntaxin since its formation in 2005, as chairman of the board. A search has been initiated for the vacant chief executive position.
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






